Indoco Remedies Limited

NSE INDOCO.NS

Indoco Remedies Limited Net Income for the year ending March 31, 2024: USD 11.80 M

Indoco Remedies Limited Net Income is USD 11.80 M for the year ending March 31, 2024, a -31.80% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.
  • Indoco Remedies Limited Net Income for the year ending March 31, 2023 was USD 17.31 M, a -15.11% change year over year.
  • Indoco Remedies Limited Net Income for the year ending March 31, 2022 was USD 20.39 M, a 60.44% change year over year.
  • Indoco Remedies Limited Net Income for the year ending March 31, 2021 was USD 12.71 M, a 297.05% change year over year.
  • Indoco Remedies Limited Net Income for the year ending March 31, 2020 was USD 3.20 M, a 865.85% change year over year.
Key data
Date Net Income EPS (Diluted) Shares (Diluted, Weighted) Net Income Margin
Market news
Loading...
NSE: INDOCO.NS

Indoco Remedies Limited

CEO Mr. Suresh Govind Kare
IPO Date Jan. 14, 2005
Location India
Headquarters Indoco House
Employees 6,000
Sector Health Care
Industries
Description

Indoco Remedies Limited manufactures and sells formulations and active pharmaceutical ingredients in India and internationally. The company offers respiratory products, such as Karvol Plus, Febrex Plus, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform Toothpaste, Sensoform Gum Paint, Rexidin M, Rexidin SRS, RR Sensoform Dental, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastrointestinal products, such as Carmicide, Cyclopam, Cyclomeff, and Nosic; pain/analgesics products that include Lignox and T-lac; and ophthal/otologicals products, such as Renolen, Homide, Dexoren – S, Zincoren, Otorex, Mofloren-D, and Mofloren LP. It also provides vitamins/minerals/nutrients that include Methycal, Cital UTI, SM Fibro, Cal Aid, SM Fibro, MCBM DHA, and Apispur; urology products, such as Carmicide and Cital; Cloben G and Scabex for dermatology; ATM for anti-infectives; Hemsyl for blood related; MCBM 69 and D Chiro for gynecological; and Spear for anti-haemorrhoidal. In addition, the company provides analytical services, such as impurity profile, particle size analysis, heavy metal analysis, polymorphism and compatibility studies, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, it offers services that include architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. The company serves general practitioners, pediatricians, consultant physicians, dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.

Similar companies

IPCALAB.NS

Ipca Laboratories Limited

USD 18.35

0.69%

HIKAL.NS

Hikal Limited

USD 4.21

4.98%

FDC.NS

FDC Limited

USD 5.56

1.72%

JBCHEPHARM.NS

J. B. Chemicals & Pharmaceuticals Limited

USD 20.35

-1.23%

SHILPAMED.NS

Shilpa Medicare Limited

USD 9.00

6.34%

StockViz Staff

January 16, 2025

Any question? Send us an email